(Q45009904)

8 December 2017

Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study (English)

1 reference

8 December 2017

1 reference

1 reference

Katz PO

1

1 reference

8 December 2017

Castell DO

2

1 reference

8 December 2017

Chen Y

3

1 reference

8 December 2017

Andersson T

4

1 reference

8 December 2017

Sostek MB

5

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Alimentary Pharmacology & Therapeutics

8 December 2017

1 reference

8 December 2017

20

1 reference

8 December 2017

4

1 reference

8 December 2017

399-406

1 reference

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

8 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

Empiric esomeprazole in the treatment of laryngopharyngeal reflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

Acid suppression in healthy subjects following lansoprazole or pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02079.X

10.1111/J.1365-2036.2004.02079.X

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference